PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3.77%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.19%. Joel Greenblatt would investigate if growth quality matches quantity.
4.12%
Cost growth of 4.12% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
2.33%
Growth of 2.33% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-1.40%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
0.17%
Operating expenses growth below 50% of Medical - Pharmaceuticals median of 1.57%. Joel Greenblatt would investigate efficiency.
3.48%
Total costs growth 1.1-1.25x Medical - Pharmaceuticals median of 2.95%. John Neff would investigate control.
-6.90%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
11.17%
D&A change of 11.17% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
8.18%
EBITDA change of 8.18% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
4.25%
Margin change of 4.25% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
11.60%
Income change of 11.60% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
7.54%
Margin change of 7.54% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-20.49%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
7.65%
Income change of 7.65% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
3.73%
Margin change of 3.73% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
8.24%
Tax expense change of 8.24% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
7.06%
Income change of 7.06% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
3.16%
Margin change of 3.16% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
7.10%
EPS change of 7.10% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
7.10%
Diluted EPS change of 7.10% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
0.00%
Share count change of 0.00% versus stable Medical - Pharmaceuticals. Walter Schloss would verify approach.
0.00%
Diluted share change of 0.00% versus stable Medical - Pharmaceuticals. Walter Schloss would verify approach.